First Drug for Post-Surgery Diabetes Complication Succeeds

Thousands of people who've had weight loss surgery may soon have help for a dangerous complication that's never had a treatment.

Amylyx Pharmaceuticals announced breakthrough results from a major clinical trial testing avexitide, a medication designed to prevent severe blood sugar crashes in people with post-bariatric hypoglycemia (PBH). The condition affects about 8% of Americans who've had gastric bypass or sleeve gastrectomy surgery, causing episodes of dangerously low blood sugar that can be disabling.

The phase 3 LUCIDITY trial enrolled 78 participants who'd undergone gastric bypass surgery. Researchers randomly assigned them to receive either a daily injection of avexitide or a placebo for several months.

The results were striking. People taking avexitide experienced 55% fewer severe low blood sugar episodes compared to those on placebo. The medication worked across multiple measures, reducing dangerous blood sugar drops whether tracked by finger pricks or continuous glucose monitors.

Even better, avexitide proved safe and easy to tolerate. Most side effects were mild to moderate, and no serious health problems were linked to the treatment during the trial.

The Ripple Effect

This success story reaches far beyond clinical trial data. For years, people living with PBH have struggled with unpredictable episodes that can cause confusion, shakiness, fainting, and even seizures. Many have had to drastically limit their daily activities, never knowing when their blood sugar might plummet. Some have faced repeated emergency room visits with no long-term solution available.

The FDA already recognized this urgent need by granting avexitide Breakthrough Therapy Designation, a status reserved for treatments addressing serious conditions with no adequate alternatives. Amylyx plans to submit their formal application for approval by year's end.

"Today's results are a major milestone that demonstrate avexitide's potential to address a critical treatment gap for the PBH community and represent a meaningful step forward for people living with this condition," said Camille L. Bedrosian, Amylyx's Chief Medical Officer.

While the approval process unfolds, Amylyx continues operating an expanded access program, allowing eligible patients to receive the medication before it reaches pharmacy shelves. This means some people struggling with PBH don't have to wait years for relief.

The broader implications extend to the growing number of Americans choosing bariatric surgery for weight management and metabolic health. As these procedures become more common and effective, addressing their complications becomes increasingly important. A proven treatment for PBH could give both patients and doctors more confidence in these life-changing surgeries.

Help is finally on the horizon for a community that's waited far too long.